14.11.2024 |
VarmX to present at LSX Investival Showcase
Investor presentation at LSX Investival Showcase, London 18 November 2024
Leiden, The Netherlands, 14 November 2024 – VarmX, a biotech company developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders will be presenting at the LSX Investival Showcase in London as part of London Life Sciences Week on 18 November 2024.
On 18 November, John Glasspool, CEO and Martijn Negen, COO will be presenting an overview of the business and its growth plans to potential investors and partners at the LSX Investival Showcase at 10.30am on the Biotech Late Growth Stage.
For more information on the LSX Investival Showcase or to register for partnering meetings, please see: https://informaconnect.com/investival-showcase/
Notes to Editors
About VarmX
VarmX is a spin-off from the Leiden University Medical Center (LUMC), founded in 2016 by Professor Pieter Reitsma, a world leading expert in hemostasis and thrombosis. VarmX’s lead compound VMX-C001 is a modified recombinant blood factor X. The compound is being developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The Company is supported by a strong syndicate of investors including Sound Bioventures, EIC, EQT Life Sciences (formerly LSP), Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures and InnovationQuarter.
For further information, please contact:
Vigo Consulting (media enquiries)
Rozi Morris
+44 20 7390 0230
Related items
10.12.2024
03.12.2024